Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 02 2022 - 8:00AM
Business Wire
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM)
(“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical
company, is pleased to announce the finalized data from the Phase 1
clinical trial of SACT-1, a repurposed small molecule drug
targeting Neuroblastoma and potentially other cancer types.
Following the announcement of the Phase 1 clinical trial of
SACT-1 in January 2022, Aptorum is pleased to announce further data
updates from the trial conducted by an independent clinical
contract research organization. The Phase 1 clinical trial of
SACT-1 was an open-label, randomized, 3-period, 3-sequence,
single-dose crossover bioavailability and food effect study of
SACT-1 (oral suspension) in healthy adult volunteers. The primary
objective of this study was to assess the relative bioavailability
of 150 mg of SACT-1 (oral suspension) under fasted and fed
conditions. The secondary objectives were to evaluate the safety,
tolerability and any potential QT prolongation after a single oral
administration of 150mg of the studied drug under fasted and fed
conditions in healthy adult subjects. The study treatments were
well tolerated and no subjects were discontinued from study
participation because of adverse events. No serious adverse events
were reported during the study. The phase 1 clinical data also
suggested that any QT interval after oral administration of SACT-1
at 150mg was well within clinically acceptable limits. Regarding
the relative bioavailability under the Fed vs Fasted condition, the
AUC0-tlast, AUC0-∞ and Cmax ratio of SACT-1 were determined to be
189.87%, 189.43%, and 205.25% respectively.
Dr. Clark Cheng, Chief Medical Officer and Executive Director of
Aptorum Group, commented: “Further to our previous announcements,
we are very encouraged by the impressive safety data even at a
relatively high dosage. The relative bioavailability data also
enabled us to estimate the starting dose for pediatric
neuroblastoma patients via PK modeling. We are planning to meet
with the US FDA for an end of Phase 1 meeting as soon as possible
and are targeting for submission for a Phase 1b/2a clinical trial
in neuroblastoma patients.”
About SACT-1
SACT-1 is an orally administered repurposed small molecule drug
to target neuroblastoma. SACT-1’s mechanism has been investigated
in our preclinical studies to enhance tumor cell death and suppress
MYCN expression (a common clinical diagnosis in high-risk or
relapsed neuroblastoma patients where an amplification of MYCN is
usually observed). SACT-1 is designed to be used especially in
combination with standard-of-care chemotherapy.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a
clinical stage biopharmaceutical company dedicated to the
discovery, development and commercialization of therapeutic assets
to treat diseases with unmet medical needs, particularly in
oncology (including orphan oncology indications) and infectious
diseases. The pipeline of Aptorum is also enriched through (i) the
establishment of drug discovery platforms that enable the discovery
of new therapeutics assets through, e.g. systematic screening of
existing approved drug molecules, and microbiome-based research
platform for treatments of metabolic diseases; and (ii) the
co-development of a novel molecular-based rapid pathogen
identification and detection diagnostics technology with Accelerate
Technologies Pte Ltd, commercialization arm of the Singapore’s
Agency for Science, Technology and Research.
For more information about the Company, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking
Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
US Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future, as well as the prospectus that received
the French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and actual results may differ
materially from those described herein.
Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided “as is” without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005452/en/
Aptorum Group Limited Investor Relations
investor.relations@aptorumgroup.com +44 20 80929299
Redchip – Financial Communications United States Investor
relations Dave Gentry dave@redchip.com +1 407 491 4498
Actifin – Financial Communications Europe Investor relations
Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024